What’s important to know about real-world evidence data collection in Germany?
In this post, I’ll summarise the key points on the real-world evidence data collection in Germany, that the G-BA can request since
German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
In this post, I’ll summarise the key points on the real-world evidence data collection in Germany, that the G-BA can request since
Welcome to another post on possible changes and the plans of the German Health Minister for the healthcare system in the next
Welcome to the last post in the HTA series, focusing on the changes to HTA and early benefit assessments in Germany in
Welcome! In this post, I am going through the steps on how the G-BA chooses the appropriate comparative therapy (ACT). I conclude
Welcome, this week’s post on the G-BA’s views on endpoints is the second article in the benefit assessments series. You’ll learn about: